[1]ºúº£á°.Çé¸ÐÓëÉç»áÐÐΪµÄÉñ¾»úÖÆÑо¿½øÕ¹[J].Öйú¿Æѧ:ÉúÃü¿Æѧ,2021,51(2):105-115.
[2]Quintana DS, Steen NE, Andreassen OA. The Promise of Intranasal Esketamine as a Novel and Effective Antidepressant[J]. JAMA Psychiatry, 2018, 75(2):123-124.
[3]Tao X, Yan M, Wang L, et al. Homeostasis Imbalance of Microglia and Astrocytes Leads to Alteration in the Metabolites of the Kynurenine Pathway in LPS-Induced Depressive-LikeMice[J]. Int J Mol Sci, 2020, 21(4):1460.
[4]Kennedy PJ, Cryan JF, Dinan TG, et al. Kynurenine pathway metabolism and the microbiota-gut-brain axis[J]. Neuropharmacology, 2017, 112(Pt B):399-412.
[5]ÍõÀöɯ,ÁõÐÂÃñ,·ëÀû,µÈ.È®Äò°±Ëáͨ·ÔÚÉñ¾ÍËÐÐÐÔ¼²²¡ÖеÄÑо¿½øÕ¹[J].Öйú±È½ÏҽѧÔÓÖ¾,2015,25(11):69-75.
[6]Muneer A. Kynurenine Pathway of Tryptophan Metabolism in Neuropsychiatric Disorders: Pathophysiologic and TherapeuticConsiderations[J]. Clin Psychopharmacol Neurosci, 2020, 18(4):507-526.
[7]¦Zzt¨¹rk M, Yal¢cn Sapmaz ÿðþ ‰C , Kandemir H, et al. The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder[J]. Int J Clin Pract, 2021,75(4):e13739.
[8]Heisler JM, O¡¯Connor JC. Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory[J]. Brain Behav Immun, 2015, 50:115-124.
[9]Ogyu K, Kubo K, Noda Y, et al. Kynurenine pathway in depression: A systematic review and meta-analysis[J]. Neurosci Biobehav Rev, 2018, 90:16-25.
[10]Kim YK, Jeon SW. Neuroinflammation and the Immune-Kynurenine Pathway in AnxietyDisorders[J]. Curr Neuropharmacol, 2018, 16(5):574-582.
[11]O¡¯Farrell K, Fagan E, Connor TJ, et al. Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary corticalneurons[J]. Eur J Pharmacol, 2017, 810:163-173.
[12]da Silveira TL, Zamberlan DC, Arantes LP, et al. Quinolinic acid and glutamatergic neurodegeneration in Caenorhabditis elegans[J]. Neurotoxicology, 2018, 67:94-101.
[13]Baranyi A, Meinitzer A, Breitenecker RJ, et al. Quinolinic Acid Responses during Interferon-alpha-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis[J]. PLoS One, 2015, 10(9):e0137022.
[14]Erhardt S, Lim CK, Linderholm KR, et al. Connecting inflammation with glutamate agonism insuicidality[J]. Neuropsychopharmacology, 2013, 38(5):743-752.
[15]Bartoli F, Misiak B, Callovini T, et al. The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and relatedmetabolites[J]. Mol Psychiatry, 26,7 (2021): 3419-3429.
[16]Wiedlocha M, Marcinowicz P, Krupa R, et al. Effect of antidepressant treatment on peripheral inflammation markers - A meta-analysis[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2018, 80(Pt C):217-226.
[17]Savitz J, Drevets WC, Wurfel BE, et al. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressivedisorder[J]. Brain Behav Immun, 2015, 46:55-59.
[18]Bay-Richter C, Linderholm KR, Lim CK, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality[J]. Brain Behav Immun, 2015, 43:110-117.
[19]Birner A, Platzer M, Bengesser SA, et al. Increased breakdown of kynurenine towards its neurotoxic branch in bipolardisorder[J]. PLoS One, 2017, 12(2):e0172699.
[20]Brundin L, Sellgren CM, Lim CK, et al. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity andneuroinflammation[J]. Transl Psychiatry, 2016, 6(8):e865.
[21]Liu X-C, Erhardt S, Goiny M, et al. Decreased levels of kynurenic acid in prefrontal cortex in a genetic animal model ofdepression[J]. Acta Neuropsychiatr, 2017, 29(1):54-58.
[22]Laumet G, Zhou W, Dantzer R, et al. Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathicpain[J]. Brain Behav Immun, 2017, 66:94-102.
[23]Zhang K, Liu R, Gao Y, et al. Electroacupuncture Relieves LPS-Induced Depression-Like Behaviour in Rats Through IDO-Mediated Tryptophan-DegradingPathway[J]. Neuropsychiatr Dis Treat, 2020, 16:2257-2266.
[24]Fischer CW, Eskelund A, Budac DP, et al. Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats[J]. Behav Brain Res, 2015, 293:166-172.
[25]Souza LC, Jesse CR, de Gomes MG, et al. Activation of Brain Indoleamine-2,3-dioxygenase Contributes to Depressive-Like Behavior Induced by an Intracerebroventricular Injection of Streptozotocin in Mice[J]. Neurochem Res, 2017, 42(10):2982-2995.
[26]Fertan E, Stover KRJ, Brant MG, et al. Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-ADMice[J]. Front Pharmacol, 2019, 10:1044.
[27]Bano S, Gitay M, Ara I, et al. Acute effects of serotonergic antidepressants on tryptophan metabolism and corticosterone levels inrats[J]. Pak J Pharm Sci, 2010, 23(3):266-272.
[28]Zhou Y, Zheng W, Liu W, et al. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression[J]. Brain Behav Immun, 2018, 74:205-212.